Skip to Content

Sandoz Fully Cooperating with European Commission Investigation of the Pharmaceuticals Industry

HOLZKIRCHEN, Germany, January 16, 2008 – Sandoz, the generics division of Novartis, announced today that it was fully cooperating with the European Commission in its investigation of the pharmaceuticals industry. Commission officials were at Sandoz companies in Holzkirchen on January 15. Based on documents presented by Commission officials to Sandoz, the investigation focuses on the market entry of innovative and generic pharmaceutical products. Sandoz intends to continue cooperating with the Commission in its investigation.


The foregoing release contains forward-looking statements that can be identified by terminology such as “intends,” or by express or implied discussions regarding the potential outcome of the investigation described in this release. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee regarding the outcome of the investigation which is described in this release. In particular, management’s expectations regarding the outcome of this investigation could be affected by, among other things, unexpected actions by the investigators, unexpected discoveries by the investigators, and other risks and factors referred to in Novartis’ current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing this information as of this date and does not undertake any obligation to update any forwardlooking statements contained in this document as a result of new information, future events or otherwise.


# # #

Kurt Leidner
Sandoz Media Relations
Tel: +49 8024 476 2591
Fax: +49 8024 476 2599
John Gilardi

Novartis Global Media Relations
Tel: +41 61 324 3018
Mobile: +41 79 596 1408

Posted: January 2008